AU2001264317A1 - Preparations for oligonucleotide transfer - Google Patents

Preparations for oligonucleotide transfer

Info

Publication number
AU2001264317A1
AU2001264317A1 AU2001264317A AU6431701A AU2001264317A1 AU 2001264317 A1 AU2001264317 A1 AU 2001264317A1 AU 2001264317 A AU2001264317 A AU 2001264317A AU 6431701 A AU6431701 A AU 6431701A AU 2001264317 A1 AU2001264317 A1 AU 2001264317A1
Authority
AU
Australia
Prior art keywords
preparations
oligonucleotide transfer
oligonucleotide
transfer
collagen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001264317A
Inventor
Masayasu Furuse
Hiroshi Itoh
Shunichiro Kubota
Shunji Nagahara
Takahiro Ochiya
Akihiko Sano
Masaaki Terada
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Koken Co Ltd
Sumitomo Pharmaceuticals Co Ltd
Original Assignee
Koken Co Ltd
Sumitomo Pharmaceuticals Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Koken Co Ltd, Sumitomo Pharmaceuticals Co Ltd filed Critical Koken Co Ltd
Publication of AU2001264317A1 publication Critical patent/AU2001264317A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/711—Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2063—Proteins, e.g. gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7007—Drug-containing films, membranes or sheets

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Dermatology (AREA)
  • Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Saccharide Compounds (AREA)

Abstract

Preparations for transferring efficiently oligonucleotides necessary in antisense therapy or the like into animal cells so as to be useful in treatment for various diseases, which comprises a collagen as an essential component are provided.
AU2001264317A 2000-06-20 2001-06-19 Preparations for oligonucleotide transfer Abandoned AU2001264317A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2000-184502 2000-06-20
JP2000184502 2000-06-20
PCT/JP2001/005195 WO2001097857A1 (en) 2000-06-20 2001-06-19 Preparations for oligonucleotide transfer

Publications (1)

Publication Number Publication Date
AU2001264317A1 true AU2001264317A1 (en) 2002-01-02

Family

ID=18684937

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001264317A Abandoned AU2001264317A1 (en) 2000-06-20 2001-06-19 Preparations for oligonucleotide transfer

Country Status (10)

Country Link
US (3) US20040052840A1 (en)
EP (1) EP1295611B1 (en)
JP (1) JP5118285B2 (en)
AT (1) ATE478688T1 (en)
AU (1) AU2001264317A1 (en)
DE (1) DE60142899D1 (en)
DK (1) DK1295611T3 (en)
ES (1) ES2349137T3 (en)
PT (1) PT1295611E (en)
WO (1) WO2001097857A1 (en)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW586934B (en) * 1997-05-19 2004-05-11 Sumitomo Pharma Immunopotentiating composition
AU2001264317A1 (en) * 2000-06-20 2002-01-02 Koken Co., Ltd. Preparations for oligonucleotide transfer
DK1407787T3 (en) * 2001-06-20 2009-06-02 Dainippon Sumitomo Pharma Co Process for promoting nucleic acid transfer
US20100104631A1 (en) * 2001-08-13 2010-04-29 Lipella Pharmaceuticals Inc. Method of treatment for bladder dysfunction
AU2003264507A1 (en) * 2002-09-20 2004-04-08 Koken Co., Ltd. Site-specific gene conversion promoter and gene therapeutic
JP4954550B2 (en) * 2003-12-19 2012-06-20 大日本住友製薬株式会社 Novel nucleic acid introduction method
US20090062184A1 (en) * 2005-03-24 2009-03-05 Dainippon Sumitomo Pharma Co., Ltd. Fine particulate preparation comprising complex of nucleic acid molecule and collagen
US7838502B2 (en) * 2005-05-06 2010-11-23 University Of Massachusetts Medical School Compositions and methods to modulate H. influenzae pathogenesis
ES2405357T3 (en) * 2005-05-25 2013-05-30 Cellmid Limited Pharmaceutical composition for occlusive vasculopathy.
KR100777249B1 (en) * 2006-02-14 2007-11-28 (주)바이오니아 Dried Oligonucleotide Composition and Method of Producing the Same
WO2010078403A2 (en) * 2008-12-30 2010-07-08 Lipella Pharmaceuticals Inc. Methods and compositions for diagnosing urological disorders
FR3066115B1 (en) * 2017-05-10 2019-06-28 Universite de Bordeaux COMPRESSES OF NUCLEIC ACID VECTORS

Family Cites Families (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5115094B2 (en) * 1972-11-01 1976-05-14
US5069936A (en) * 1987-06-25 1991-12-03 Yen Richard C K Manufacturing protein microspheres
US5078997A (en) * 1988-07-13 1992-01-07 Cetus Corporation Pharmaceutical composition for interleukin-2 containing physiologically compatible stabilizers
US5098890A (en) * 1988-11-07 1992-03-24 Temple University-Of The Commonwealth System Of Higher Education Antisence oligonucleotides to c-myb proto-oncogene and uses thereof
US5936035A (en) * 1988-11-21 1999-08-10 Cohesion Technologies, Inc. Biocompatible adhesive compositions
US5614587A (en) * 1988-11-21 1997-03-25 Collagen Corporation Collagen-based bioadhesive compositions
JP3187410B2 (en) * 1989-08-10 2001-07-11 住友製薬株式会社 Sustained release formulation for intracerebral administration
US5542935A (en) * 1989-12-22 1996-08-06 Imarx Pharmaceutical Corp. Therapeutic delivery systems related applications
US5264618A (en) * 1990-04-19 1993-11-23 Vical, Inc. Cationic lipids for intracellular delivery of biologically active molecules
FR2694895B1 (en) * 1992-08-20 1994-11-10 Coletica Process for the production of emulsion microparticles by modification of the chemical composition of the dispersed phase after emulsification.
US5646042A (en) * 1992-08-26 1997-07-08 Ribozyme Pharmaceuticals, Inc. C-myb targeted ribozymes
EP0745092B1 (en) * 1993-05-28 1999-07-21 Chiron Corporation Peptide inhibitors of urokinase receptor activity
KR960704526A (en) * 1993-09-09 1996-10-09 베. 클로제·우베 하르트만 Active Principles and Gas Containing Microparticles
CA2140053C (en) * 1994-02-09 2000-04-04 Joel S. Rosenblatt Collagen-based injectable drug delivery system and its use
US5942496A (en) * 1994-02-18 1999-08-24 The Regent Of The University Of Michigan Methods and compositions for multiple gene transfer into bone cells
US5583034A (en) * 1994-02-22 1996-12-10 La Jolla Institute For Allergy And Immunology Enhancement of adoptosis using antisense oligonucleotides
US5844107A (en) * 1994-03-23 1998-12-01 Case Western Reserve University Compacted nucleic acids and their delivery to cells
US5563255A (en) * 1994-05-31 1996-10-08 Isis Pharmaceuticals, Inc. Antisense oligonucleotide modulation of raf gene expression
AU2946295A (en) * 1994-06-27 1996-01-19 Johns Hopkins University, The Targeted gene delivery system
WO2001074342A2 (en) * 2000-03-31 2001-10-11 Trustees Of Boston University Use of locally applied dna fragments
EP0844004B1 (en) * 1995-07-03 2007-09-12 Koken Co., Ltd. Collagen containing gene preparations
US6998268B2 (en) * 1995-07-03 2006-02-14 Dainippon Sumitomo Pharma Co. Ltd. Gene preparations
JP3867160B2 (en) * 1995-07-03 2007-01-10 大日本住友製薬株式会社 Gene preparation
KR19990066967A (en) * 1995-10-23 1999-08-16 둘헌티 브리안 Gene therapy for treating abnormal retinal angiogenesis and hyaluronic acid used as a DNA carrier for VEGF antisense
PT876165E (en) * 1995-12-18 2006-10-31 Angiotech Biomaterials Corp COMPOSITIONS OF RETICULATED POLYMERS AND PROCESSES FOR THEIR USE
AU728146B2 (en) * 1996-03-14 2001-01-04 Immune Response Corporation, The Targeted delivery of genes encoding interferon
US6133437A (en) * 1997-02-13 2000-10-17 Apoptogen, Inc. Modulation of IAPs for the treatment of proliferative diseases
US5874006A (en) * 1996-10-31 1999-02-23 Matrix Pharmaceutical, Inc. Aseptic collagen concentration process
US6042820A (en) * 1996-12-20 2000-03-28 Connaught Laboratories Limited Biodegradable copolymer containing α-hydroxy acid and α-amino acid units
US6218112B1 (en) * 1996-12-23 2001-04-17 Cobra Therapeutics Limited Optimization of gene delivery and gene delivery system
WO1998030575A1 (en) * 1997-01-08 1998-07-16 Proligo Llc Bioconjugation of macromolecules
US6524613B1 (en) * 1997-04-30 2003-02-25 Regents Of The University Of Minnesota Hepatocellular chimeraplasty
EP1054694A2 (en) * 1998-02-13 2000-11-29 Selective Genetics, Inc. Concurrent flow mixing methods and apparatuses for the preparation of gene therapy vectors and compositions prepared thereby
EP1078639A4 (en) * 1998-05-22 2004-10-06 Sumitomo Pharma Stable gene preparations
AU2001264317A1 (en) * 2000-06-20 2002-01-02 Koken Co., Ltd. Preparations for oligonucleotide transfer
JP2002325572A (en) * 2000-12-25 2002-11-12 Univ Osaka Method for introducing exogenous substance
DK1407787T3 (en) * 2001-06-20 2009-06-02 Dainippon Sumitomo Pharma Co Process for promoting nucleic acid transfer
US7148342B2 (en) * 2002-07-24 2006-12-12 The Trustees Of The University Of Pennyslvania Compositions and methods for sirna inhibition of angiogenesis
US20060030534A1 (en) * 2002-09-04 2006-02-09 Gabriele Dorn Treatment of neurological disorders by dsrna administration
AU2003264507A1 (en) * 2002-09-20 2004-04-08 Koken Co., Ltd. Site-specific gene conversion promoter and gene therapeutic
US7521431B2 (en) * 2002-11-01 2009-04-21 The Trustees Of The University Of Pennsylvania Compositions and methods for siRNA inhibition of HIF-1 alpha
MXPA05007651A (en) * 2003-01-16 2005-10-26 Univ Pennsylvania COMPOSITIONS AND METHODS FOR siRNA INHIBITION OF ICAM-1.
US8227434B1 (en) * 2003-11-04 2012-07-24 H. Lee Moffitt Cancer Center & Research Institute, Inc. Materials and methods for treating oncological disorders
ES2523147T3 (en) * 2004-02-26 2014-11-21 Baylor Research Institute Compositions and methods for the systemic treatment of arthritis
JP4991547B2 (en) * 2004-09-28 2012-08-01 クアーク・ファーマスーティカルス、インコーポレイテッド Oligoribonucleotides and methods of use thereof for the treatment of alopecia, acute renal failure and other diseases
CN101060863B (en) * 2004-10-22 2012-06-06 拉瓦勒大学 Modulation of neuroglia-derived BDNF in the treatment and prevention of pain
US7585848B2 (en) * 2005-01-11 2009-09-08 Rush University Medical Center Methods and compositions for treating, inhibiting and reversing disorders of the intervertebral disc
EP1983823A1 (en) * 2006-01-17 2008-10-29 VIB vzw Inhibitors of prolyl-hydroxylase 1 for the treatment of skeletal muscle degeneration
CA2655355C (en) * 2006-06-16 2014-05-06 Taisho Pharmaceutical Co., Ltd. Use of rpn2 gene expression inhibitor
US8232256B2 (en) * 2006-07-21 2012-07-31 Silence Therapeutics Ag Means for inhibiting the expression of protein kinase 3
WO2008028085A2 (en) * 2006-08-30 2008-03-06 The Board Of Trustees Of The University Of Illinois Modulation of mlck-l expression and uses thereof
CA2665202A1 (en) * 2006-10-02 2008-04-10 Aprea Ab Compounds and methods
US7812002B2 (en) * 2007-03-21 2010-10-12 Quark Pharmaceuticals, Inc. Oligoribonucleotide inhibitors of NRF2 and methods of use thereof for treatment of cancer
WO2011069155A1 (en) * 2009-12-04 2011-06-09 Opko Ophthalmics, Llc Compositions and methods for inhibition of vegf

Also Published As

Publication number Publication date
EP1295611A4 (en) 2009-07-08
DE60142899D1 (en) 2010-10-07
EP1295611B1 (en) 2010-08-25
PT1295611E (en) 2010-09-14
US20110028535A1 (en) 2011-02-03
DK1295611T3 (en) 2010-10-04
US20040052840A1 (en) 2004-03-18
EP1295611A1 (en) 2003-03-26
US20090258933A1 (en) 2009-10-15
ATE478688T1 (en) 2010-09-15
JP5118285B2 (en) 2013-01-16
ES2349137T3 (en) 2010-12-28
WO2001097857A1 (en) 2001-12-27

Similar Documents

Publication Publication Date Title
EP1190099A4 (en) Antisense modulation of pi3k p85 expression
WO2002036743A3 (en) Antisense modulation of calreticulin expression
HK1044723A1 (en) Mixing/charging port for medical treatment.
AU4208100A (en) Soft tissue heating apparatus with independent, cooperative heating sources
EP1248794A4 (en) Antisense modulation of smad7 expression
HK1033278A1 (en) Pharmaceutical preparation for use in anti-asthma therapy.
AU2001264317A1 (en) Preparations for oligonucleotide transfer
AU2002317651A1 (en) Hog manure treatment system
WO2001032832A3 (en) Antisense inhibition of nucleolin expression
MXPA03000574A (en) Glass-ceramics, process for their preparation and use.
EP1189918A4 (en) Antisense modulation of integrin beta 3 expression
HK1044725A1 (en) Mixing/charging port for medical treatment.
WO2001029175A3 (en) Antisense modulation of fra-1 expression
EP1218398A4 (en) Antisense modulation of pi3 kinase p110 beta expression
AU2001283322A1 (en) Organic nutrient for hair loss treatment
AU2180501A (en) Novel DNA polymerase inhibitors, mikanolide and dihydromikanolide
WO2001031051A3 (en) Antisense modulation of protein kinase c-theta expression
WO2002050248A3 (en) Antisense modulation of hepsin expression
EP1250347A4 (en) Antisense modulation of akt-3 expression
WO2004010956A3 (en) Antisense modulation of lar expression
EP1165145A4 (en) Antisense modulation of mdmx expression
ZA200200731B (en) Novel strategy for carbohydrate-based therapeutic vaccines.
EP1235924A4 (en) Antisense modulation of rank expression
AU2002218164A1 (en) Animal feed supplement containing d-pantothenic acid and/or its salts, improved method for the production thereof, and its use
ZA200104596B (en) IBDV strain for in ovo administration.